ATYR today
$6.11-$0.10 (-1.69%)close Nov 13, 2026Trend
DailyUptrend (starting)
4 hourStrong Bearish
1 hourStrong Bearish
15 minStrong Bearish
5 minStrong Bearish
Daily trend turns down below $0.10
Key levels
Resistance$7.65
Resistance$6.44
Support$5.30
Support$4.32
Latest news & SEC filings
DealaTyr Pharma registers $80M stock sale program with Jefferies as agent
All ATYR news →About aTyr Pharma
aTyr Pharma is a biotech firm that turns tRNA synthetase science into drug candidates for scarring and inflammatory conditions. Its main drug, efzofitimod, is being tested in patients with lung diseases marked by immune-driven inflammation, including sarcoidosis and scleroderma-related lung involvement. Earlier-stage programs ATYR0101 and ATYR0750 target fibrotic conditions. The company is based in the United States and works with a partner in Japan.
Based on the company's 10-K filed Mar 5, 2026.
Nasdaq · Healthcare
aTYR PHARMA INC (ATYR)
What Is the Price Target for ATYR?
SEPT Low Target
$4.00
SEPT Mid Target
$5.00
SEPT High Target
$6.00
Analyst Consensus
$5.00
Is ATYR a Buy or Sell Right Now?
Thesis
- •Revenue growing -19.1% YoY with ACCELERATING trend — accelerating momentum.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for ATYR.
Start Free Trial →Is ATYR Overvalued or Undervalued?
Valuation Verdict
OVERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$4.05
15
Moat Score
NONE
1/9
Piotroski Score
N/A
Altman Z-Score
What Is Smart Money Doing with ATYR?
Insider Signal
NEUTRAL
1 buys / 3 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| SCHIMMEL PAUL | director | Buy | 100,000 | $50K | May 27, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →ATYR Growth Story
Revenue YoY
-19.1%
3yr Revenue CAGR
-73.7%
EPS Growth YoY
6.98%
FCF Growth YoY
10.3%
Revenue Trend
ACCELERATING
Dark Pool Trades for ATYR
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for ATYR, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 15:14:32 | $6.10 | 1,291 | $$8K | SELL |
| 20:31:02 | $6.48 | 2,075 | $$13K | BUY |
| 20:17:22 | $6.31 | 1,520 | $$10K | BUY |
| 15:44:05 | $6.23 | 1,250 | $$8K | SELL |
| 18:21:05 | $6.93 | 1,273 | $$9K | SELL |
5 dark pool trades shown · $$48K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for aTYR PHARMA INC (ATYR) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (2 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →ATYR — frequently asked questions
What is ATYR stock price today?
aTYR PHARMA INC (ATYR) is at $6.11, down 1.69% (-$0.10) at the Nov 13, 2026 close.
Why is ATYR stock moving today?
Latest ATYR news — Nov 6, 2026: aTyr Pharma registers $80M stock sale program with Jefferies as agent
Why did ATYR stock move on Nov 6, 2026?
aTyr Pharma shares jumped 11.40% to close at $6.35, trading between a low of $5.70 and a high of $6.64 on volume of 60,123. The move came alongside a Q3 2026 financial and business update, while the company also registered an $80 million stock sale program with Jefferies as agent, a potential dilution overhang.
What is the ATYR price target?
The average analyst price target for ATYR is $5.00, ranging from $4 to $6, based on 2 analysts. Latest: RBC Capital maintains on Nov 6, 2026.
What do analysts rate ATYR?
Analyst ratings for ATYR: 4 Buy, 5 Hold, 0 Sell — consensus Buy.
Did ATYR beat earnings?
ATYR last reported on Nov 5, 2026: EPS $0.53 vs -$4.00 expected — a beat of 113.3%.
Does ATYR pay a dividend?
ATYR does not currently pay a dividend.
What are ATYR support and resistance levels?
Support: $5.30, $4.32, $2.98. Resistance: $6.44, $7.65.
What are insiders doing with ATYR?
Insider activity: NEUTRAL, 1 buys and 3 sells in the last 90 days.
What is the latest news on ATYR?
Nov 6, 2026: aTyr Pharma registers $80M stock sale program with Jefferies as agent